British shoe retailer Dr. Martens Plc has not experienced any surprises in the first few months of the 2023/24 financial year, which has been running since the beginning of April. Business development has so far been “in line with expectations” and the forecasts presented at the beginning of June, the company said on Thursday in the run-up to its annual general meeting. Concrete figures were not published.
The results in the EMEA region, which includes Europe, the Middle East and Africa, were, as expected, “very pleasing” in the first quarter, according to an interim report. The long-established company has also achieved “good growth” in the Asia-Pacific region, not least thanks to strong business in Japan.
In America, on the other hand, sales fell short of the previous year’s level due to the weak wholesale business. The company emphasized that getting the ongoing problems in this region under control remains management’s “first priority”. In the company’s own retail business in America, the measures that have since been introduced are making “progress according to plan”, but visible “significant improvements” are only to be expected in the second half of the year.